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Abstract
Activation of Natural Killer-like T cells (NKT) with the CD1d ligand a-GC leads to enhanced production of anthrax toxin
protective Ag (PA)-neutralizing Abs, yet the underlying mechanism for this adjuvant effect is not known. In the current
study we examined the role of Th1 and Th2 type responses in NKT-mediated enhancement of antibody responses to PA.
First, the contribution of IL-4 and IFNc to the production of PA-specific toxin-neutralizing Abs was examined. By immunizing
C57Bl/6 controls IL-4
2/2 mice and IFNc
2/2 mice and performing passive serum transfer experiments, it was observed that
sera containing PA-specific IgG1, IgG2b and IgG2c neutralized toxin in vitro and conferred protection in vivo. Sera
containing IgG2b and IgG2c neutralized toxin in vitro but were not sufficient for protection in vivo. Sera containing IgG1
and IgG2b neutralized toxin in vitro and conferred protection in vivo. IgG1 therefore emerged as a good correlate of
protection. Next, C57Bl/6 mice were immunized with PA alone or PA plus a Th2-skewing a-GC derivative known as OCH.
Neutralizing PA-specific IgG1 responses were modestly enhanced by OCH in C57Bl/6 mice. Conversely, IgG2b and IgG2c
were considerably enhanced in PA/OCH-immunized IL-4
2/2 mice but did not confer protection. Finally, bone marrow
chimeras were generated such that NKT cells were unable to express IL-4 or IFNc. NKT-derived IL-4 was required for OCH-
enhanced primary IgG1 responses but not recall responses. NKT-derived IL-4 and IFNc also influenced primary and recall
IgG2b and IgG2c titers. These data suggest targeted skewing of the Th2 response by a-GC derivatives can be exploited to
optimize anthrax vaccination.
Citation: Devera TS, Joshi SK, Aye LM, Lang GA, Ballard JD, et al. (2011) Regulation of Anthrax Toxin-Specific Antibody Titers by Natural Killer T Cell-Derived IL-4
and IFNc. PLoS ONE 6(8): e23817. doi:10.1371/journal.pone.0023817
Editor: Dennis W. Metzger, Albany Medical College, United States of America
Received April 22, 2011; Accepted July 27, 2011; Published August 17, 2011
Copyright:  2011 Devera et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by Defense Threat Reduction Agency (DTRA) contract HDTRA1-08-C-0013 to MLL. Approval for public release of the information
herein was required and obtained from DTRA prior to submission of the manuscript. The funders had no role in study design, data collection and analysis,o r
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mark-lang@ouhsc.edu
Introduction
The protective Ag (PA) protein secreted by Bacillus anthracis is an
83 kDa protein that forms heptameric pores on the surface of
target cells expressing anthrax toxin receptors (capillary morpho-
genesis protein-2, CMG-2 and tumor endothelial marker-8,TEM-
8) [1,2]. PA heptamers interact with lethal factor (LF) and edema
factor (EF) to form lethal toxin (LT) and edema toxin (ET), which
together are referred to as anthrax toxin [2]. The PA heptamer
facilitates entry of EF and LF into the target cell. Following cell
entry, EF generates supra-physiological levels of cAMP via the
protein’ calmodulin-dependent adenylate cyclase activity [3].
Within the intoxicated cell LF functions as a zinc-dependent
metalloprotease and cleaves mitogen activated protein kinase
kinases. LT can also activate the inflammasome in rodent models
of intoxication [4]. Both toxins are lethal in animal models and
cause a broad range of defects in target cells, including altered cell
cycle, cell growth and survival, and attenuated inflammatory
responses [5]. Collectively these activities of anthrax toxin cripple
the host immune system and allow B. anthracis to grow to high
numbers in the bloodstream [2,6,7,8,9]. Hence, immune neutral-
ization of PA counters the damaging effects of anthrax toxin,
providing protection to the host during early stages of disease.
PA-specific Ab neutralizes LT and ET in vitro and protects
immunized animals in vivo following a lethal challenge with the
toxins [10,11,12,13,14,15]. There is a good correlation between
PA-specific Ab titers and toxin neutralization by sera from patients
who have survived B. anthracis infection [16]. Consequently, there
is considerable interest in development of vaccines which
incorporate PA as the immunogen but involves fewer immuniza-
tions, boosts immunological memory and prolongs neutralizing Ab
production while stimulating a minimal inflammatory response
[16,17]. The current AVA anthrax vaccine administered to US
military personnel consists of PA and induces PA-specific Ab titers
sufficient to neutralize anthrax toxin [16,17]. However, the Anti-
PA Ab titers are not sustained and individuals require adminis-
tration of multiple booster vaccines to maintain toxin-neutralizing
Ab titers (http://www.anthrax.osd.mil/vaccine/schedule.asp#).
Thus, there is a need for improving the efficacy of the current
anthrax vaccine. Towards this effort, we recently demonstrated
that activation of CD1d-restricted NKT cells with the CD1d-
binding ligand (a-galactosylceramide, a-GC) at the time of
immunization with PA led to enhanced and sustained Ab-
mediated protection against anthrax lethal toxin [18]. Recent
work by our laboratory and others has shown that NKT activation
improves Ab responses against model and pathogen-derived Ags,
suggesting that study of responses to anthrax could be useful for
future application to other pathogens [19,20,21,22,23].
The mechanism by which a-GC-activated NKT cells provide
help to PA-specific B cells is not clear, and whether a-GC
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unknown. The a-GC ligand consists of a galactose headgroup with
an a-anomeric linkage to hydrophobic sphingosine and acyl
chains. The lipid moiety is loaded into hydrophobic pockets in the
CD1d molecule expressed by professional Ag-presenting cells,
orienting the galactose headgroup for recognition by NKT cells
[24,25]. The predominant NKT subset is represented by the Type
I NKT cells which express an invariant Va14, Ja18 TCR in mice
and a Va24, Ja28 TCR in humans [24,25]. Type II NKT cells are
CD1d-restricted, have variable Va usage and are thought to be
stimulated by a variety of self glycolipids rather than a-GC
[24,25].
Several researchers are investing considerable effort in designing
a-GC-based molecules that have improved or more selective
adjuvant effects than a-GC. Those focused on vaccines for cancer
and malaria designed CD1d ligands that stimulate Th1-driven
immune responses [26,27]. The production of Th1 cytokines such
as IFNc by NKT cells and throughout the immune system is a
reasonable indicator of how various CD1d ligands may function to
impact Th1-driven immunity. In contrast, a-GC-related molecules
have received little attention in the context of specific Ab responses
that may be Th1 or Th2-driven.
We therefore examined the contribution of NKT cell-derived
Th2 and Th1 cytokines to the production of PA-specific toxin-
neutralizing Abs. Using IL-4
2/2 and IFNc
2/2 mice, and bone
marrow chimeric mice we demonstrate that a Th2-skewing CD1d
ligand (OCH) modulates production of anthrax-toxin specific Ab
subclasses. We show that the production of IgG1, IgG2b and
IgG2c are affected by NKT-derived IL-4 and IFNc. These
findings provide much needed insight into a mechanism that can
be exploited to optimize anthrax vaccination.
Materials and Methods
Reagents
BL21 competent cells were purchased from Invitrogen (Carls-
bad, CA). The pET15b plasmids encoding PA and LF respectively
were a gift from Dr. J. Collier (Harvard Medical School) and have
been described previously [1]. The protein assay kit was purchased
from Bio-Rad Laboratories (Hercules, CA). The Pyrogent Ultra
Limulus Amebocyte Lysate kit was purchased from Lonza
(Walkersville, MD). HRP-conjugated anti-IgG1 was purchased
from Southern Biotechnology (Birmingham, AL). Fluorochrome-
conjugated mAbs were purchased from BD Biosciences (San Jose,
CA). The FccR-blocking mAb (2.4G2) was purchased from
BioXpres (West Lebanon, NH). CD1d tetramers (loaded with
synthetic a-GC, PBS57) and the CD1d ligand OCH were
provided by the NIAID Tetramer Facility (Emory University,
Atlanta, GA). The a-GC ligand was purchased from Axorra Inc.
(San Diego, CA).
Toxin Expression and Purification
Histidine-tagged PA and LF were expressed separately in
competent BL21 Escherichia coli (Invitrogen, Carlsbad, CA)
transformed with the pET15b-rPA, pET15b-rLF and
pET15brLF
H690C plasmids respectively. PA and LF were then
purified from bacterial lysates using standard methods also
described previously [28]. In brief, PA and LF purification was
achieved using a 5 ml HisTrap FF affinity column (GE Life-
Sciences, Piscataway, NJ). LPS contamination was removed by
from purified PA and LF using an EndoTrap Red LPS-binding
affinity column (Lonza, Walkersville, MD). The concentration of
residual endotoxin was determined using the Limulus Assay,
which has a sensitivity of 0.06 Endotoxin Units/ml (6 pg/ml)
(Lonza). The final preparation used for this study contained
40 ng/ml LPS in the PA and was below the limits of detection for
the LF. No more than 4 ng LPS was administered to each mouse
in experiments described herein. Of note, Histidine tags on
anthrax toxin proteins did not induce anti-His Ab responses
[29,30].
Mice
Female C57Bl/6 mice (CD45.2- and CD45.1-congenic) were
purchased from the National Cancer Institute (Bethesda, MD). IL-
4
2/2 and IFNc
2/2 mice on a homogenous C57Bl/6 (CD45.2)
genetic background were purchased from the Jackson Laboratory
(Bar Harbor, ME). Ja18
2/2 mice have a gene deletion in the TCR
locus preventing rearrangement of the TCR gene specific to Type I
NKT cells reactive to a-GC and related ligands [31]. Ja18
2/2 mice
were kindly provided by Dr. Kronenberg (La Jolla Institute for
Allergy and Immunology, La Jolla, CA) following permission from
Dr. Taniguchi (RIKEN Institute, Riken, Japan). The Ja18
2/2
colony was maintained in a barrier facility at OUHSC. All
experiments, unless indicated otherwise were commenced on mice
at 6–10 wk of age.
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal procedures reported herein were approved by the
University of Oklahoma Health Sciences Center Institutional
Animal Care and Use Committee (IACUC). Protocol 10-085-HI
was issued to authorize the experiments described herein. Unless
indicated otherwise, procedures were performed under inhala-
tional isofluorane anesthesia (96% oxygen, 4% isofluorane), and all
efforts were made to minimize suffering. Procedure associated-
deaths precluded the use of anesthesia for in vivo lethal challenge
assays. This method was approved by the IACUC and performed
by a qualified veterinarian (S.K. Joshi DVM).
Isolation of splenocytes and bone marrow
Spleens were harvested into RPMI buffer and a single cell
suspension obtained by mechanical disruption. Bone marrow cells
were flushed from the femurs and tibias using a 27 gauge needle
and syringe filled with media. Erythocytes were removed by
incubation with ammonium chloride lysis buffer (0.16 M NH4Cl,
0.17 M Tris-HCl, pH 7.4) for 2 min at 37uC. After washing in
culture media, cell viability was confirmed as .98% by trypan
blue exclusion. Cells were enumerated using a Nexelom cell
counter (Lawrence, MA).
Bone Marrow Chimeras
Naı ¨ve 6 wk old female C57Bl/6 CD45.1 congenic mice were
irradiated (700 Rad) and rested for 18 h before a second
irradiation (500 Rad). After a further 4 h, donor bone marrow
cells were transferred by the i.v. route to the irradiated recipients.
One million donor cells were transferred and all donor mice
expressed the CD45.2 allele. Donor bone marrow consisted of the
following 50:50 mixtures: Ja18
2/2/C57Bl/6; Ja18
2/2/IL-4
2/2;
Ja18
2/2/IFNc
2/2. Recipient mice were then housed for a period
of 12 wk. Mice were either euthanized or immunized and
subsequently bled as described. Euthanized mice were used as a
source of cells for analysis of re-engraftment of the bone marrow,
re-constitution of the lymphoid and myeloid compartments in the
periphery, and in vitro functional assays.
NKT-Enhanced Anti-Toxin Responses
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Female mice of 6–10 wk of age were used and five mice per
group were immunized unless indicated otherwise. A single
subcutaneous (s.c.) immunization was administered over both
flanks on d 0 immediately following collection of pre-bleed sera.
Unless indicated otherwise, immunizations consisted of 10 mgP A
in 200 ml sterile-endotoxin-free PBS or PA mixed with 4 mgo f
OCH. Mice were then bled at d 14 post-immunization and sera
obtained. On d 28 mice were bled and then boosted s.c. with 5 mg
of PA in PBS and bled on d 45 and between d 110–120 unless
indicated otherwise. At the end of the experimental period, mice
were either challenged with toxin or euthanized in order to obtain
bone marrow and spleen.
Retro-orbital eye bleed and serum collection
Mice were anesthetized using a vaporized 4% isofluorane/96%
oxygen mixture and 100 ml blood collected by retro-orbital bleed
with heparinized micro-capillary tubes (Fisher Scientific, Hamp-
ton, NH). Samples were transferred immediately to polypropylene
micro-centrifuge tubes. Blood samples were incubated for 30 min
at room temperature then allowed to clot overnight at 4uC, before
centrifugation at 13,000 g for 15 min at 4uC. Sera were withdrawn
with a pipette and stored in aliquots at 220uC.
Passive transfer Experiments
C57Bl/6 mice were immunized s.c. with 10 mg PA on d 0 and
boosted with PA on d 28. Sera were collected every two d starting
on d 38 and ending on d 48. Sera from different time points and
the different mice within the same group were then pooled. Sera
were also collected from naı ¨ve mice and pooled. A five hundred
microliter volume of sera was then transferred by the i.p. route to
recipient IL-4
2/2 mice. After further 24 h of incubation, mice
were challenged with LT.
In Vivo Toxin Challenge
The LF and PA subunits were mixed at a 1:1 molar ratio in
PBS. An amount of lethal toxin equivalent to 200 mg PA and in a
100 ml volume was then administered by the i.v. paraorbital route
to mice. After 24 h a second dose equivalent to 100 mg PA was
administered. The mice were then monitored daily for the
duration of the experiment and time to death or euthanasia was
recorded by a qualified DVM. Pain and suffering were minimized
as follows: The mice were housed with food and water ad libitum
with a 12 hr light/dark cycle; Mice were kept in groups of 5 in
their own cage throughout the experiments; If mice were observed
to have progressed to hunched posture, ruffled fur, self-imposed
isolation, slow movement and tremors, they were euthanized.
Toxin administration is typically associated with few immediately
visible effects in C57Bl/6 mice and is followed by rapid worsening
and death. Otherwise, death was the experimental endpoint. A
Log-rank Mantel-Cox test in conjunction with Kaplan-Meier
survival curves was used to measure differences between
experimental groups.
ELISA for Serum Ig
Immulon 4 ELISA–plates (Dynex Technologies Inc. Chantilly,
VA), were coated with PA at 10 mg/ml in binding buffer (0.1 M
Na2HPO4, pH 9.0), overnight at 4uC before washing plates and
blocking for 2 h at room temperature with 1.0% w/v BSA in
PBS/0.05% v/v Tween 20. Sera were diluted 100 or 10,000 fold
in PBS/0.05% v/v Tween and subjected to two-fold serial
dilutions, before adding to PA-coated, pre-blocked plates. Plates
were incubated overnight at 4uC with diluted sera, before washing
4 times in PBS/0.05% v/v Tween 20. Plates were incubated for
1 h at room temperature with HRP-conjugated anti-mouse IgG1,
IgG2b or IgG2c at a final concentration of 0.2 mg/ml. Plates were
washed and developed for 8 min at room temperature using 90 ml
of ABTS substrate per well (KPL, Gaithersburg, MD). Reactions
were stopped by addition of 110 ml of a 10% w/v SDS solution.
Plates were analyzed using a Dynex MRX Revelation plate
reader. Endpoint titers were determined as O.D. ,0.01 at 405 nm
(equivalent to O.D. of 1/200 dilution of pre-bleed sera or two-
times background). Individual Ab titers were plotted as geometric
means using GraphPad Prism software. A non-parametric Mann-
Whitney U test was used to assess experiments with two
experimental groups. Where titers were not detectable, a value
of 100 was assigned corresponding to the highest concentration of
serum in the assay. Multiple experimental groups were assessed by
one-way ANOVA with Dunn’s post-test.
In Vitro Toxin Neutralization Assay
Murine 264.7 macrophages were adjusted to 10
6 cells/ml in
DMEM containing 4 mM L-glutamine, 10% FCS and 40 mg/ml
gentamicin. One hundred thousand cells in a 100 ml volume were
then seeded into 96 well culture plates and incubated overnight
with 5% CO2. Serial two-fold dilutions of sera in media were
made (1/125–1/500), mixed with lethal toxin at a final
concentration of 1–16 mg/ml of each subunit. The toxin mixture
was then incubated for 1 h at room temperature. Media were then
removed from cell cultures and replaced with the sera/toxin/
media mixture. Plates were incubated for a further 2 h at 37uC
before addition of Cell counting Kit-8 (Dojindo Technologies,
Rockville, MD). After 2 h incubation, plates were read at an
absorbance of 450 nm. Differences in Ab titers between two
experimental groups were assessed for statistical significance using
a non-parametric Mann-Whitney U test. As with ELISA
experiments the Mann Whitney U test was used because an
independent control was performed for each experimental group.
Flow Cytometry
Cells were incubated at 4uC or room temperature at a density of
10
7 cells/ml in RPMI plus 10% FCS with 2.4G2 mAb at a final
concentration of 20 mg/ml. Fluorochrome-conjugated mAbs were
added at a 1:100 to a 1:500 dilution as appropriate or with APC-
conjugated CD1d tetramer at a 1:250 dilution. After 1 h unbound
mAb was removed by washing and centrifugation. Cells were fixed
with 1% w/v para-formaldehyde and analyzed using a Becton-
Dickinson FACSCalibur (Palo Alto, CA).
Cytokine Assays
Mice were immunized i.p. with 4 mg a-GC or 4 mg OCH in a
100 ml volume of PBS/0.05% v/v Tween 20. Sera were collected
before immunization and at 6 and 22 h thereafter. Samples were
analyzed using an IFNc or IL-4 sandwich ELISA in accordance
with the manufacturer’s instructions (BD Biosciences, Mountain
View, CA) and as described previously [32].
Results
Requirement for IL-4 but not IFNc in the production of
lethal toxin neutralizing Ab
Experiments were performed to determine which Ab subclasses
accounted for protection against LT in vivo in the C57Bl/6 mouse
strain. C57Bl/6 control mice and IL-4
2/2 and IFNc
2/2 mice on
the C57Bl/6 genetic background were immunized s.c. with 10 mg
PA on d 0 and boosted with 5 mg of PA on d 28. Blood samples
were collected and sera prepared on d 28, 42 and 113, previously
NKT-Enhanced Anti-Toxin Responses
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primary, recall, and long-term Ab titers [33] (Figure 1). Endpoint
anti-PA IgG1, IgG2b and IgG2c titers were determined by ELISA
(Figure 1A–C). IgG2c rather than IgG2a was assayed because the
c2a gene segment is deleted in the C57Bl/6 genetic background
[34]. In C57Bl/6 and IFNc
2/2 mice, IgG1 was the predominant
Ab subclass produced. Titers were higher following the booster
vaccine than in primary sera and were sustained over the course of
the experiment. In IL-4
2/2 mice, there was a marked absence of
IgG1 production, but high IgG2b and IgG2c titers were observed.
These data show as expected that IL-4 was required for
production of anti-PA IgG1. In contrast, IFNc was dispensable
for IgG1 production, but drove IgG2b and IgG2c production in
the absence of IL-4.
Sera from immunized C57Bl/6, IL-4
2/2 and IFNc
2/2 mice
were then used to determine the ability of anti-PA Ab to neutralize
LT in vitro (Figure 2A). In each of the three mouse strains used the
neutralization capacity corresponded to the Ab titers regardless of
subclass, showing that a combination of: IgG1, IgG2b and IgG2c;
IgG2b and IgG2c; or IgG1 and IgG2b were capable of
neutralizing LT in vitro. The immunized C57Bl/6, IL-4
2/2 and
IFNc
2/2 mice were also administered a lethal dose of LT by the
i.v. route on d 115 and survival was monitored over a 12 d period
(Figure 2B). C57Bl/6 and IFNc
2/2 mice showed a transient
worsening in health over 48 h followed by recovery, and
ultimately survived the challenge. In contrast, all IL-4
2/2 mice
displayed rapidly worsening health, and died within 96 h of the
challenge. These data show that while sera containing IgG1,
IgG2b and IgG2c, IgG1 and IgG2b or containing IgG2b and
IgG2c adequately neutralized LT in vitro, the latter did not confer
adequate protection in vivo.
Since death in the IL-4
2/2 mice could have been attributed to a
defect other than lack of IgG1, sera were collected from naı ¨ve and
PA-immunized C57Bl/6 (containing IgG1, IgG2b and IgG2c) and
transferred to naı ¨ve IL-4
2/2 mice before LT challenge
(Figure 2C). In that experiment, 75% of mice that received sera
from the PA-immunized mice survived. In contrast 0% of the mice
that received sera from the naı ¨ve mice survived, confirming that
lack of survival of IL-4
2/2 mice was attributable to a lack of PA-
specific IgG1 rather than another IL-4-associated defect.
Effect of Th2-polarizing CD1d ligand OCH on production
of lethal toxin-neutralizing IgG1
It was reported previously that the CD1d ligand a-GC which
stimulates a mixed Th1/Th2 response in vivo, led to production of
PA-specific, IgG1, IgG2b and IgG2c, albeit dominated by the
IgG1 subclass [33]. In this study, IgG1, IgG2b and IgG2c-
containing sera were more protective in vivo than sera containing
IgG2b and IgG2c, implicating IgG1 as a good correlate of in vivo
protection. C57Bl/6 mice were therefore immunized with PA or
PA plus OCH (an a-GC variant). OCH has weaker activity than
a-GC and skews NKT cells to Th2 cytokine production [35,36].
PA/OCH administration was followed by a booster vaccine
consisting of PA. Sera were collected before (d 28) and after (d 45
and 113) the booster and PA-specific endpoint IgG1, IgG2b and
IgG2c titers determined by ELISA. OCH enhanced the anti-PA
IgG1 and IgG2b responses measured on d 28, but had no
measurable effect on longer-term titers measured at d 45 and 113
(Figure 3A–B). OCH had no effect on IgG2c responses measured
at d 28, d 45 or d 113 (Figure 3C). As a further control C57Bl/6
mice were immunized with vehicle, a-GC or OCH, before
collecting sera and measuring IL-4 and IFNc production. The
selective production of IL-4 in the C57Bl/6 environment following
OCH administration confirmed that the response to OCH was
Th2-polarized (Figure S1). Therefore the result show that a Th2-
skewing OCH boosted toxin-specific primary IgG1 and IgG2b
responses in C57Bl/6 mice but did not offer the sustained response
previously observed for the a-GC ligand [18]. This suggests that a
Th2-skewing CD1d ligand can accelerate the primary IgG1 and
IgG2b response but does not increase the ultimate Ab titer
following a booster vaccine.
Figure 1. Requirement for IL-4 and IFNc in production of PA-
specific IgG1 or IgG2c. C57Bl/6, IL-4
2/2 and IFNc
2/2 mice were
immunized and bled as described. A Endpoint anti-PA IgG1, B IgG2b,
and C IgG2c titers were determined by ELISA. Each data point
represents an individual mouse and geometric mean titers are shown.
Data are representative of three independent experiments. Statistical
significance (p,0.05) is indicated by asterisks.
doi:10.1371/journal.pone.0023817.g001
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2/2 mice
C57Bl/6 and IL-4
2/2 mice were immunized and bled as
described in materials and methods, except that the experiment
was shortened to duration of 45 days. This permitted toxin
challenge when IgG2b and IgG2c titers were highest. In C57Bl/6
mice, OCH had a similar effect on the d 45 IgG1, IgG2b and
IgG2c titers as compared to the previous experiment in Figure 3,
although the adjuvant effect was less apparent in d 28 bleeds
(Figure 4A–C). OCH did not induce measurable IgG1 responses
in IL-4
2/2 mice, but did significantly boost IgG2b and IgG2c
titers. This showed that OCH-stimulated IL-4
2/2 NKT cells were
capable of boosting IgG2b and IgG2c responses. Further
examination of the sera using ELISA plates coated with high
versus low concentrations of PA, revealed that OCH did not affect
the overall affinity of PA-specific IgG1, IgG2b or IgG2c in C57Bl/
6 or IL-4
2/2 mice (Figure S2).
Sera from immunized C57Bl/6 and IL-4
2/2 mice were then
tested for neutralization of anthrax toxin in vitro (Figure 5A).
OCH led to an enhanced in vitro neutralization by d 28 sera from
C57Bl/6 mice but not IL-4
2/2 mice. On subsequent bleeds (d 45)
Figure 2. Requirement for IL-4 but not IFNc in production of
PA-neutralizing IgG. A Sera from experiment in Figure 1 were tested
for their ability to protect RAW267.4 macrophages from LT toxicity.
Graph shows neutralization by sera from C57Bl/6 mice, IL-4
2/2 and
IFNc
2/2 mice. Each data point represents an individual mouse and the
mean survival of the cell line following treatment with LT and sera is
indicated. B Mice were challenged with LT as indicated. C Pooled sera
from naı ¨ve (n=5) and PA-immunized (n=5) mice were transferred to
naı ¨ve IL-4
2/2 mice before challenge with LT. Three and four IL-4
2/2
mice per group received naı ¨ve and immune sera respectively. Data in A
and B are representative of two independent experiments while data in
C are from a single experiment. Graphs show percent survival following
LT administration. Statistical significance (p,0.05) is indicated by
asterisks.
doi:10.1371/journal.pone.0023817.g002
Figure 3. Effect of OCH on PA-specific IgG1, IgG2b and IgG2c
response. C57Bl/6 mice were immunized and bled as described. A
Endpoint anti-PA IgG1, B IgG2b and C IgG2c titers were determined by
ELISA. Each data point represents an individual mouse (5 per group)
and geometric mean titers are shown. Data are representative of two
independent experiments. Statistical significance (p,0.05) is indicated
by asterisks.
doi:10.1371/journal.pone.0023817.g003
NKT-Enhanced Anti-Toxin Responses
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Figure 2, sera from immunized C57Bl/6 and IL-4
2/2 mice had
comparable in vitro neutralization. The immunized C57Bl/6 and
IL-4
2/2 mice were challenged with LT (on d 48). Survival was
monitored daily (Figure 5B, C). C57Bl/6 mice immunized with
PA alone had a 60% survival rate following toxin challenge,
whereas 100% of mice immunized with PA plus OCH survived.
Although modest, the differences were statistically significant
(Figure 5C). This is consistent with the Ab titer and neutralization
data shown in Figure 3 and 4, showing that OCH has a moderate
effect on protective IgG1 responses. In contrast, PA-immunized
IL-4
2/2 mice all died within 6 d of toxin challenge, consistent with
results in Figure 1. IL-4
2/2 mice immunized with PA plus OCH
died steadily in the days following challenge and had a 0% survival
rate over 9 d that did not differ significantly from the control group
(Figure 5C). These results showed that a Th2-skewing CD1d
ligand could stimulate a Th1 Ab response in the absence of IL-4.
Modulation of PA-specific IgG1, IgG2b and IgG2c by NKT-
derived IL-4 and IFNc
Bone marrow chimeras were constructed in which NKT cells
could or could not express IL-4 or IFNc while other immune cells
retained the capacity for IL-4 and IFNc production (Figure 6).
Three different chimeras were constructed whereby irradiated
recipient mice were engrafted with a 50:50 mix of donor bone
marrow from Ja18
2/2 mice and C57Bl/6 mice (Ja18
2/2/C57Bl/
6), with a 50:50 mix from Ja18
2/2 mice and IL-4
2/2 mice
Figure 4. OCH-enhanced IgG2b and IgG2c responses in IL-4
2/2
mice. C57Bl/6 and IL-4
2/2 mice were immunized and bled as described
in materials and methods. A Shows endpoint anti-PA IgG1 titers. B
Shows endpoint anti-PA IgG2b titers. C Shows endpoint anti-IgG2c
titers. Each data point represents an individual mouse (4 or 5 per group
as indicated) and geometric mean titers are shown. Data are
representative of two independent experiments.
doi:10.1371/journal.pone.0023817.g004 Figure 5. Non-protective OCH-enhanced IgG2b and IgG2c
responses in IL-4
2/2 mice. A Sera from mice in Figure 4 were
tested for neutralization of LT in vitro. B C57Bl/6 and C IL-4
2/2 mice
were challenged as indicated. Toxin was administered on d 50 when
IgG2 titers were highest. Graphs show percent survival following LT
administration. Statistical significance (p,0.05) is indicated by asterisks.
Each data point in A represents an individual mouse (4 or 5 per group
as indicated). All mice in A were challenged for parts B and C. Data are
representative of two independent experiments.
doi:10.1371/journal.pone.0023817.g005
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2/2/IL-4
2/2) or with a 50:50 mix from Ja18
2/2 mice and
IFNc
2/2 mice (Ja18
2/2/IFNc
2/2) (Figure 6A). All three
chimeras were equivalently reconstituted with major immune cell
types that were donor-derived (Figure S3) and had equivalent
expression of CD1d and re-constitution of the NKT compartment
(Figure 6B).
Ja18
2/2/C57Bl/6, Ja18
2/2/IL-4
2/2 and Ja18
2/2/IFNc
2/2
chimeras were immunized with PA alone or PA plus OCH and
later boosted with PA alone (Figure 6C). Primary and recall sera
were collected and a contribution of NKT-derived IL-4 was
apparent for the d 28 IgG1 response, but not for the d 45 and 117
responses. Absence of NKT-derived IFNc had no discernable
effect on IgG1 titers. These data indicate that NKT-derived IL-4
accelerated the production of PA-specific IgG1. In the Ja18
2/2/
IL-4
2/2 chimeras, IgG2b and IgG2c were boosted by OCH. In
contrast, OCH had no measurable adjuvant effect on IgG2b and
IgG2c in the Ja18
2/2/IFNc
2/2 chimeras (Figure 6C). These
results show that NKT cell-derived IL-4 accelerates PA-specific
IgG1 responses, but suppresses PA-specific IgG2c responses. In
contrast, NKT-derived IFNc is dispensable for IgG1 production
but contributory to the IgG2b and IgG2c responses.
We performed experiments to measure in vitro LT neutraliza-
tion by sera obtained from the chimeric mice (Figure S4). We
observed that all sera from the d 45 bleeds exhibited neutralization
of LT in vitro. There was apparent variance in neutralization
between experimental groups but comparison between PA- and
PA/OCH-immunized groups or between the chimeras did not
show statistically significant differences. The PA/OCH-immu-
nized mice were challenged with LT 120 d after immunization. All
groups succumbed with a similar time-course and all mice died
within 6 d of LT administration, suggesting that bone marrow
chimeric mice are too susceptible to LT for the challenge
experiments routinely carried out on the C57Bl/6 background
(data not shown).
Discussion
The objective of this study was to identify critical elements of
NKT-dependent vaccination against anthrax toxin and use this
information to improve production of neutralizing antibodies
targeting PA. To achieve this goal, it was necessary to revisit the
question of which murine IgG subclasses confer protection against
anthrax toxin. A number of studies have shown that following PA
immunization, IgG1, IgG2 and IgG3 subclasses can all be
observed [37]. Studies using mAbs of known subclass have
elegantly demonstrated that IgG1 or IgG2a can be harmful or
beneficial to macrophages in vitro by affecting cellular entry of
toxin [38]. It is therefore possible, perhaps likely, that harmful and
beneficial Abs of all subclasses are formed during an in vivo
polyclonal response to immunization. We therefore obtained IL-
4
2/2 mice and IFNc
2/2 mice on the C57Bl/6 genetic
background. These strains are well known for their poor capacity
to stimulate production of IgG1 and IgG2c respectively [39,40],
and it was therefore expected that they would be unable to
produce PA-specific IgG1 or IgG2c (as was observed). The sera
from immunized C57Bl/6, IL-4
2/2 and IFNc
2/2 mice were all
able to neutralize PA in vitro but sera containing IgG2b and
IgG2c was at least as protective in vitro as sera containing IgG1,
IgG2b and IgG2c or containing IgG1 and IgG2b.
For reasons that are presently unclear OCH boosted primary
IgG1 responses in C57Bl/6 mice, but only secondary responses in
IL-4
2/2 mice. This suggests NKT-derived IL-4 may boost the
primary response and suppress the memory response induced by
OCH. Exploration of this concept would require adoptive transfer
approaches using congenic recipients to delineate between
primary and recall Ab titers in the strains used and is warranted
in future studies.
The in vitro neutralization assays contrasted with the in vivo
challenge experiments because IL-4
2/2 mice lacking anti-PA
IgG1 were not protected against LT. In that experiment, IFNc
2/2
mice with IgG1 and IgG2b but no IgG2c were protected similarly
to C57Bl/6 controls containing IgG1, IgG2b and IgG2c. These
results therefore suggest the possibility that a polyclonal PA-
specific IgG1 response is more protective in vivo than a polyclonal
IgG2b or IgG2c response. This was confirmed by transfer of sera
PA-immunized C57Bl/6 mice into naı ¨ve IL-4
2/2 recipients,
whereby protection was conferred. The reason for the lack of
protection conferred by IgG2b and IgG2c in the IL-4
2/2 mice is
presently unclear. Arguably, the absolute amount of IgG2b and
IgG2c titers in immunized mice could have been insufficient to
neutralize toxin. However, IgG2b titers at the time of in vivo toxin
challenge in PA/OCH-immunized IL-4
2/2 mice were compara-
ble to IgG1 titers in PA/OCH-immunized C57Bl/6 mice and
three-fold higher than in PA-immunized C57Bl/6 mice (Figure 4).
Under these conditions, the IL-4
2/2 mice were still less protected
than the PA- or the PA/OCH-immunized C57Bl/6 mice. Given
that the different IgG sub-classes were detected using the same
methods and reagents (with the exception of the detection Ab),
then it is not highly likely that the amount of IgG2b and IgG2c
was too low to be protective.
An alternative explanation is that collectively IgG1, IgG2b and
IgG2c are required for protection, perhaps by invoking a range of
effector mechanisms, however, IFNc
2/2 mice lacked IgG2c
responses and displayed comparable neutralization and survival
as the C57Bl/6 controls. Another potential explanation is that the
different cytokine environments affected the specificity of the anti-
PA IgG responses. However, in IFNc
2/2 mice we did not observe
changes in protection. Arguably Ab specificities could be different
in IL-4
2/2 mice, but with a polyclonal response, this does not
appear likely. Epitope mapping studies would be required to
address this hypothesis.
It was recently found that mAbs with the same PA-specificity
recombined with IgG1, IgG2a and IgG2b constant regions were
all protective in vivo (when the same dose was administered) and
that IgG2a was superior to IgG1. Furthermore, the protection was
FccR dependent [41]. It is difficult to directly compare the results
of that study with our findings, since that study compared IgG2a to
IgG1 and passive transfer of monoclonal responses was examined.
Arguably by transferring IgG2a into a mouse strain that does not
normally express it, the IgG2a subclass may have had an
exaggerated protective effect in vivo due to lack of competition
for FcR binding by other IgG2a molecules. Equally possible
however, is that IgG1 could have assumed a more exaggerated
role in our experiments (as compared to IgG2b and IgG2c)
because IgG2a was absent. Clearly, neither of these studies
represents the last word in regard to which Ab classes are optimal
for protection, but indicate that there is considerable complexity in
the neutralizing Ab response that warrants further analysis.
Given that sera containing IgG1, IgG2b and IgG2c or
containing IgG1 and IgG2b was more protective than serum
containing IgG2b and IgG2c in vivo, we tested a Th2 cytokine-
polarizing CD1d ligand known as OCH [36]. OCH is similar in
structure to the better known a-GC molecule that stimulates a
mixed Th1/Th2 response, except that it has a truncated
sphingosine chain and a slightly shortened acyl chain. We
observed that OCH enhanced the primary IgG1 response, and
to a lesser extent the recall IgG1 response, but did not polarize Ab
production away from IgG2b or IgG2c. Consequently, there was
NKT-Enhanced Anti-Toxin Responses
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23817Figure 6. Modulation of PA-specific IgG1, IgG2b and IgG2c by NKT-derived IL-4 and IFNc.ABone marrow chimeras were generated as
indicated and detailed in materials and methods. B Splenocytes from chimeras were analyzed by flow cytometry for expression of CD1d (histograms)
and re-constitution of CD1d-tetramer
+/TCRb
+ NKT cells (dot plots). Mean fluorescent intensity for anti-CD1d mAb binding and percent frequency of
CD1d-tetramer
+/TCRb
+ cells are indicated. Comparable numbers of total splenocytes were recovered from each chimera indicating comparable
absolute numbers of NKT cells. Reconstitution of cell populations and NKT cells has been demonstrated in at least 6 independent experiments. C
Chimeric mice were immunized and bled as described. Top row shows endpoint anti-PA IgG1 titers on the days indicated following immunization.
Middle row shows endpoint anti-PA IgG2b titers. Bottom row shows endpoint anti-IgG2c titers. Each data point represents an individual mouse (5–7
per group as indicated). Data are representative of two similar independent experiments (except for a-GC as adjuvant). Statistical significance
(p,0.05) is indicated by asterisks. Further statistical comparisons (ANOVA) were employed to compare the d45 bleeds for IgG2b and IgG2c between
the three different chimeras. The IgG2b and IgG2c titers were significantly lower in the Ja18
2/2/IFNc
2/2 chimeras than the Ja18
2/2/IL-4
2/2 chimeras
but not the Ja18
2/2/C57Bl/6 chimeras (not depicted on figure).
doi:10.1371/journal.pone.0023817.g006
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mice as regards in vitro neutralization or in vivo protection.
Furthermore, OCH was unable to overcome the lack of IgG1
production in IL-4
2/2 mice, but significantly boosted IgG2b and
IgG2c titers. These experiments suggested a functional dissociation
between the reported mechanisms of action of OCH (IL-4
production by NKT cells) and its effects on an NKT-enhanced
Ab response. We therefore conducted experiments to ask directly
whether NKT-derived IL-4 or IFNc had any influence on the
anti-PA Ab profile. Bone marrow chimeras whereby all NKT cells
were able to express IFNc and IL-4, IFNc only or IL-4 only were
created, immunized and bled. The data revealed that NKT-
derived IL-4 accelerated the production of anti-PA IgG1. This was
evident in the reduced primary IgG1 responses following PA/
OCH administration in chimeras lacking NKT-derived IL-4.
The absence of NKT-derived IL-4 did not substantially impact
recall IgG1 titers. It is noteworthy that in the chimeras, we have
frequently observed that OCH (and a-GC) do not lead to as great
an enhancement of recall Ab responses as in C57Bl/6 mice. This
experimental system could therefore not be used to rule out effects
of IL-4 on recall IgG1 responses. An alternative explanation is that
other NKT-derived Th2 cytokines such as IL-13 compensate for
the lack of IL-4. However, in IL-4
2/2 mice, NKT cell stimulation
was unable to generate an IgG1 response.
NKT-derived IL-4 and IFNc also affected IgG2b and IgG2c
production. In the presence of IL-4
2/2 NKT cells, there was an
enhancement of the anti-PA IgG2b and IgG2c responses. In
contrast, there was a near absence of OCH adjuvant effect on anti-
PA IgG2b and IgG2c in the presence of IFNc
2/2 NKT cells.
These results suggest that one function of NKT-derived IFNc
might be to boost production of less abundant Ab subclasses,
whereas IL-4 may suppress that response.
We have therefore shown in this study that NKT-derived
cytokines can exert modulating effects on toxin-neutralizing Ab
responses, but have differential impacts on distinct Ab subclasses.
Our results may have impact in two areas. Firstly, assessing IL-4
and IFNc production by NKT cells in response to stimulation with
various CD1d ligands may not be a sufficient indicator of the
ensuing immune response, particularly with regards to Th2-driven
humoral responses. Secondly, vaccination strategies that seek to
harness NKT activation may need to take account of the Ab
subclasses that are beneficial or harmful against a given pathogen.
Supporting Information
Figure S1 Polarized Th2 response in mice stimulated
with OCH. C57Bl/6 mice were immunized i.p. with vehicle
(PBS/Tween), vehicle plus a-GC, or vehicle plus OCH. Sera were
collected prior to immunization and at 6 and 22 h thereafter.
Concentration of IL-4 and IFNc in the samples was then
determined by sandwich ELISA. Data shows mean cytokine
concentration for 3 (a-GC) and 5 (OCH) mice per group.
CD1d
2/2 were also treated but did not elicit any measurable
response to a-GC or OCH (not depicted).
(TIF)
Figure S2 Affinity of PA-specific IgG1, IgG2b or IgG2c
are not affected by OCH or by lack of IL-4. Invivo d 45sera
from experiment reported in Figure 4 were assessed by ELISA.
Plates were coated with PA at a final concentration of 2 mg/ml and
20 mg/ml respectively. Sera at a 1/1000 dilution were then
incubatedontheplatewithbothPAconcentrationsbeforedetection
of Ab sub-classes. Bar graphs indicate the mean 6SD ratio of the
A405 for samples applied to the 2 mg/ml wells versus the 20 mg/ml
wells indicating the proportion of high affinity Ab in the samples.
(TIF)
Figure S3 Effective reconstitution of the hematopoetic
compartment following lethal irradiation. Spleens were
obtained from immunized Ja18
2/2/C57Bl/6, Ja18
2/2/IL-4
2/2
and Ja18
2/2/IFNc
2/2 chimeric mice and analyzed by flow
cytometry. Top row shows CD45.2
+/+ donor cells and residual
CD45.1
+/+ recipient cells in re-constituted mice. Second row
shows re-constitution with donor-derived T cells. Third row shows
re-constitution with donor-derived B cells. Fourth row shows re-
constitution with donor-derived dendritic cells.
(TIF)
Figure S4 In vitro neutralization of lethal toxin by sera
from PA-immunized chimeric mice. The d 45 sera from the
experiment in Figure 6 were tested for their ability to protect
RAW267.4 macrophages from LT toxicity. Graph shows neutrali-
zation by sera from Ja18
2/2/C57Bl/6, Ja18
2/2/IL-4
2/2 and
Ja18
2/2/IFNc
2/2 chimeras. Each data point represents an
individual mouse and the mean survival of the RAW267.4
macrophages following treatment with LT and sera is indicated.
One of the sera from the Ja18
2/2/C57Bl/6 group immunized with
PA was not analyzed due to an insufficient amount of sample
remaining.
(TIF)
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